Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Document Type
- Journal article (15)
- Preprint (1)
Language
- English (16)
Keywords
- gephyrin (4)
- X-ray crystallography (3)
- Cryo-EM (2)
- GABA (2)
- PIP2 (2)
- artemisinin (2)
- diazepam (2)
- inhibitory neurotransmission (2)
- AAA+ ATPase p97 (1)
- African sleeping sickness (1)
- CIB1 (1)
- Crystal structure of MTR1 (1)
- Cys-loop receptor (1)
- DNA structures (1)
- E1 (1)
- GABA(A) receptors (1)
- GABAA (1)
- GABAA receptors (1)
- GapN (1)
- MYCNv (1)
- Methyltransferase Ribozyme MTR1 (1)
- NADPH (1)
- NMR spectroscopy (1)
- PNA (peptide nucleic acid) (1)
- RNA (1)
- RNA structures (1)
- RNA-catalyzed RNA methylation (1)
- Rho GTPase (1)
- activation (1)
- autoinhibition (1)
- binding (1)
- biosensor (1)
- calmodulin (1)
- channel (1)
- chronophin (1)
- complex (1)
- computational docking (1)
- conjugation (1)
- containing GABA(A) receptors (1)
- covalent inhibitors (1)
- cultured hippocampal-neurons (1)
- domain (1)
- dominant (1)
- drug target (1)
- electron microscopy (1)
- enzyme mechanisms (1)
- exchange factor collybistin (1)
- expression (1)
- fluorescence resonance energy transfer (FRET) (1)
- fragment screening (1)
- gamma-aminobutyric-acid (1)
- glycine (1)
- glycine receptor (1)
- glycine transporter 2 (1)
- glycolytic flux control (1)
- glyvine uptake (1)
- guanine nucleotide exchange factor (GEF) (1)
- haloacid dehalogenase (1)
- homology modeling (1)
- hyperekplexia (1)
- inhibitory postsynapse (1)
- inhibitory synapse (1)
- intrinsic metabolism (1)
- ligand potencies (1)
- ligases (1)
- loop B (1)
- loss of function (1)
- mechanisms (1)
- molybdenum cofactor biosynthesis (1)
- mutations (1)
- neddylation (1)
- neural networks (1)
- neuroblastoma cell (1)
- pathway (1)
- phosphoglycolate phosphatase (1)
- post-translational modifications (1)
- presynaptic hyperekplexia (1)
- proteasome system (1)
- protein NEDD8 (1)
- protein structures (1)
- protein transport (1)
- purification (1)
- pyridoxal phosphatase (1)
- quantum chemistry (1)
- rat spinal-cord (1)
- receptor clustering (1)
- receptor-beta subunits (1)
- scaffolding protein gephyryrin (1)
- side chain properties (1)
- site (1)
- startle (1)
- structural biology (1)
- structural disruption (1)
- synapse formation (1)
- system (1)
- temporal-lobe epilepsy (1)
- trafficking (1)
- vitamin B6 (1)
Institute
- Rudolf-Virchow-Zentrum (15)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Institut für Klinische Neurobiologie (2)
- Institut für Pharmakologie und Toxikologie (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Institut für Organische Chemie (1)
- Institut für Physikalische und Theoretische Chemie (1)
Sonstige beteiligte Institutionen
Interneuronal synaptic transmission relies on the proper spatial organization of presynaptic neurotransmitter release and its reception on the postsynaptic side by cognate neurotransmitter receptors. Neurotransmitter receptors are incorporated into and arranged within the plasma membrane with the assistance of scaffolding and adaptor proteins. At inhibitory GABAergic postsynapses, collybistin, a neuronal adaptor protein, recruits the scaffolding protein gephyrin and interacts with various neuronal factors including cell adhesion proteins of the neuroligin family, the GABAA receptor α2-subunit and the closely related small GTPases Cdc42 and TC10 (RhoQ). Most collybistin splice variants harbor an N-terminal SH3 domain and exist in an autoinhibited/closed state. Cdc42 and TC10, despite sharing 67.4% amino acid sequence identity, interact differently with collybistin. Here, we delineate the molecular basis of the collybistin conformational activation induced by TC10 with the aid of recently developed collybistin FRET sensors. Time-resolved fluorescence-based FRET measurements reveal that TC10 binds to closed/inactive collybistin leading to relief of its autoinhibition, contrary to Cdc42, which only interacts with collybistin when forced into an open state by the introduction of mutations destabilizing the closed state of collybistin. Taken together, our data describe a TC10-driven signaling mechanism in which collybistin switches from its autoinhibited closed state to an open/active state.
The strict human pathogen Streptococcus pyogenes causes infections of varying severity, ranging from self-limiting suppurative infections to life-threatening diseases like necrotizing fasciitis or streptococcal toxic shock syndrome. Here, we show that the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase GapN is an essential enzyme for S. pyogenes. GapN converts glyceraldehyde 3-phosphate into 3-phosphoglycerate coupled to the reduction of NADP to NADPH. The knock-down of gapN by antisense peptide nucleic acids (asPNA) significantly reduces viable bacterial counts of S. pyogenes laboratory and macrolide-resistant clinical strains in vitro. As S. pyogenes lacks the oxidative part of the pentose phosphate pathway, GapN appears to be the major NADPH source for the bacterium. Accordingly, other streptococci that carry a complete pentose phosphate pathway are not prone to asPNA-based gapN knock-down. Determination of the crystal structure of the S. pyogenes GapN apo-enzyme revealed an unusual cis-peptide in proximity to the catalytic binding site. Furthermore, using a structural modeling approach, we correctly predicted competitive inhibition of S. pyogenes GapN by erythrose 4-phosphate, indicating that our structural model can be used for in silico screening of specific GapN inhibitors. In conclusion, the data provided here reveal that GapN is a potential target for antimicrobial substances that selectively kill S. pyogenes and other streptococci that lack the oxidative part of the pentose phosphate pathway.
The absence of fluorine from most biomolecules renders it an excellent probe for NMR spectroscopy to monitor inhibitor–protein interactions. However, predicting the binding mode of a fluorinated ligand from a chemical shift (or vice versa) has been challenging due to the high electron density of the fluorine atom. Nonetheless, reliable \(^{19}\)F chemical‐shift predictions to deduce ligand‐binding modes hold great potential for in silico drug design. Herein, we present a systematic QM/MM study to predict the \(^{19}\)F NMR chemical shifts of a covalently bound fluorinated inhibitor to the essential oxidoreductase tryparedoxin (Tpx) from African trypanosomes, the causative agent of African sleeping sickness. We include many protein–inhibitor conformations as well as monomeric and dimeric inhibitor–protein complexes, thus rendering it the largest computational study on chemical shifts of \(^{19}\)F nuclei in a biological context to date. Our predicted shifts agree well with those obtained experimentally and pave the way for future work in this area.
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.
Biosensor techniques have become increasingly important for fragment-based drug discovery during the last years. The AAA+ ATPase p97 is an essential protein with key roles in protein homeostasis and a possible target for cancer chemotherapy. Currently available p97 inhibitors address its ATPase activity and globally impair p97-mediated processes. In contrast, inhibition of cofactor binding to the N-domain by a protein-protein-interaction inhibitor would enable the selective targeting of specific p97 functions. Here, we describe a biolayer interferometry-based fragment screen targeting the N-domain of p97 and demonstrate that a region known as SHP-motif binding site can be targeted with small molecules. Guided by molecular dynamics simulations, the binding sites of selected screening hits were postulated and experimentally validated using protein- and ligand-based NMR techniques, as well as X-ray crystallography, ultimately resulting in the first structure of a small molecule in complex with the N-domain of p97. The identified fragments provide insights into how this region could be targeted and present first chemical starting points for the development of a protein-protein interaction inhibitor preventing the binding of selected cofactors to p97.
Ligand-binding of Cys-loop receptors is determined by N-terminal extracellular loop structures from the plus as well as from the minus side of two adjacent subunits in the pentameric receptor complex. An aromatic residue in loop B of the glycine receptor (GIyR) undergoes direct interaction with the incoming ligand via a cation-π interaction. Recently, we showed that mutated residues in loop B identified from human patients suffering from hyperekplexia disturb ligand-binding. Here, we exchanged the affected human residues by amino acids found in related members of the Cys-loop receptor family to determine the effects of side chain volume for ion channel properties. GIyR variants were characterized in vitro following transfection into cell lines in order to analyze protein expression, trafficking, degradation and ion channel function. GIyR α1 G160 mutations significantly decrease glycine potency arguing for a positional effect on neighboring aromatic residues and consequently glycine-binding within the ligand-binding pocket. Disturbed glycinergic inhibition due to T162 α1 mutations is an additive effect of affected biogenesis and structural changes within the ligand-binding site. Protein trafficking from the ER toward the ER-Golgi intermediate compartment, the secretory Golgi pathways and finally the cell surface is largely diminished, but still sufficient to deliver ion channels that are functional at least at high glycine concentrations. The majority of T162 mutant protein accumulates in the ER and is delivered to ER-associated proteasomal degradation. Hence, G160 is an important determinant during glycine binding. In contrast, 1162 affects primarily receptor biogenesis whereas exchanges in functionality are secondary effects thereof.